School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, PR China.
State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, PR China.
Bioorg Med Chem Lett. 2024 Nov 15;113:129972. doi: 10.1016/j.bmcl.2024.129972. Epub 2024 Sep 21.
In this work, two series of water-soluble derivatives were designed and synthesized based on the structure of propofol as the lead compound. Furthermore, the anesthetic activities of the synthesized compounds were evaluated in vivo against mice, and the in vitro propofol release rate from five target compounds was determined. The findings of this study have shown that series II compounds which possess the structure feature of propofol + γ-hydroxybutyric acid + α-aminoacetate or γ-aminobutyrate have higher therapeutic index than that of series I compounds which possess the structure feature of propofol + α-aminoacetate or β-aminopropionate. In addition, the rate of propofol released from series II compounds was significantly better than that of series I compounds. Among series II compounds, compound II-20 had a therapeutic index of 5.6 (propofol = 2.7), a duration time of 571 s (propofol = 57 s), and no significant toxicity was observed in vivo, which made it valuable for further development.
在这项工作中,我们基于丙泊酚的结构设计并合成了两系列水溶性衍生物。此外,我们还评估了合成化合物在体内对小鼠的麻醉活性,并测定了 5 种目标化合物的体外丙泊酚释放率。研究结果表明,具有丙泊酚+γ-羟基丁酸+α-氨基乙酸或γ-氨基丁酸结构特征的 II 系列化合物比具有丙泊酚+α-氨基乙酸或β-氨基丙酸盐结构特征的 I 系列化合物具有更高的治疗指数。此外,II 系列化合物中丙泊酚的释放速率明显优于 I 系列化合物。在 II 系列化合物中,化合物 II-20 的治疗指数为 5.6(丙泊酚=2.7),持续时间为 571s(丙泊酚=57s),且体内未见明显毒性,具有进一步开发的价值。